1. Homepage
  2. Equities
  3. China
  4. Shanghai Stock Exchange
  5. Gan & Lee Pharmaceuticals.
  6. News
  7. Summary
    603087   CNE100003ZH1

GAN & LEE PHARMACEUTICALS.

(603087)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Gan & Lee Pharmaceuticals : & Lee Pharma's Tumor Drug Wins Orphan Drug Designation in Europe

04/06/2021 | 11:41pm EDT


ę MT Newswires 2021
All news about GAN & LEE PHARMACEUTICALS.
04/27Gan & Lee Pharmaceuticals. Reports Earnings Results for the First Quarter Ended March 3..
CI
03/10Gan & Lee Pharmaceuticals Begins First-In-Human Trial in U.S. for Investigational Drug,..
AQ
03/10Gan & Lee Pharmaceuticals. Begins First-In-Human Trial in U.S. for Investigational Drug..
CI
2021Gan & Lee Pharmaceuticals Co., Ltd. Announces U.S. FDA Clearance of Investigational New..
CI
2021China’s Drug Procurement Program Cuts Insulin Costs by Around 48%
MT
2021Gan & Lee Pharmaceuticals. Reports Earnings Results for the Nine Months Ended September..
CI
2021GAN & LEE PHARMACEUTICALS : Concludes Phase 3 Studies of Gan & Lee Insulin Glargine (GL-GL..
AQ
2021Gan & Lee Pharmaceuticals. Reports Earnings Results for the Half Year Ended June 30, 20..
CI
2021GAN & LEE PHARMACEUTICALS : New Data on Phase 1 Proposed Biosimilar Gan & Lee Insulins Asp..
AQ
2021Gan & Lee Pharmaceuticals Co., Ltd. Announces Positive Phase 1 Clinical Trial Results a..
CI
More news
Financials
Sales 2022 4 002 M 593 M 593 M
Net income 2022 1 533 M 227 M 227 M
Net Debt 2022 - - -
P/E ratio 2022 15,5x
Yield 2022 -
Capitalization 23 764 M 3 519 M 3 519 M
Capi. / Sales 2022 5,94x
Capi. / Sales 2023 4,90x
Nbr of Employees 3 278
Free-Float 20,5%
Chart GAN & LEE PHARMACEUTICALS.
Duration : Period :
Gan & Lee Pharmaceuticals. Technical Analysis Chart | 603087 | CNE100003ZH1 | MarketScreener
Technical analysis trends GAN & LEE PHARMACEUTICALS.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 1
Last Close Price 42,32
Average target price
Spread / Average Target -
EPS Revisions
Managers and Directors
Zhong Ru Gan Chairman
Yan Sun Independent Director
Yan Qing He Independent Director
Guo Jun Zheng Independent Director
Kai Du Director & Director-International Department
Sector and Competitors
1st jan.Capi. (M$)
GAN & LEE PHARMACEUTICALS.-39.84%3 541
CSL LIMITED-5.73%92 626
SAMSUNG BIOLOGICS CO.,LTD.-12.18%42 971
BIOGEN INC.-15.43%29 715
WUXI BIOLOGICS (CAYMAN) INC.-41.33%29 181
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.-25.03%22 156